HEAR IT FIRST WITH OUR DAILY NEWSLETTER



We don't spam. Learn more about our Privacy Policy

Special Report: MGC Pharma’s proven CannEpil treatment has touched down in Australia.

Australian epilepsy sufferers now have a pathway to access to MGC Pharma’s new CannEpil treatment after its arrival into the country for supply under the Authorised Prescriber Scheme.

It’s a significant milestone for the medical cannabis and biopharma company (ASX:MXC), which has been steadily working on making CannEpil available.

CannEpil is an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, which accounts for about 30 per cent of all epilepsy cases.

Back in October, a number of prescribing specialist neurologists received formal authorisation to prescribe it in Australia under the Authorised Prescriber Scheme.

Now, CannEpil is available via those authorised prescribers.

It will initially be stored at St Vincent’s Hospital in Melbourne and distributed nationwide by specialist Australian pharmaceutical distributor HL Pharma.

Up to 25,000 Australians are diagnosed with epilepsy each year and some 240,000 are living with epilepsy, according to Epilepsy Action Australia (EAA).

>> ASX listed cannabis stocks: here’s everything you need to know

The long road to get here

Roby Zomer, co-founder and chief of MGC, said the milestone symbolised the completion of the final step before full commercialisation of its first investigational medicinal product (IMP).

“The arrival of CannEpil in Australia is a great achievement for us on our pathway to growing and commercialising the company as a European-based, pure biopharma company,” he said.

“We have been working extremely hard to get to this stage and we are all very excited to see the first sales of CannEpil achieved.”

One of MGC’s medical advisory board members, Associate Professor Wendyl D’Souza, is a leading neurologist and epileptologist and an Authorised Prescriber of medicinal cannabis in Australia.

He has treated over 3,000 patients with drug-resistant epilepsy and is driving further development of CannEpil.

CannEpil has been independently tested and certified as complying with product quality guidelines and strict European Good Manufacturing Practice standards.

The product’s arrival into Australia also followed authorisation from the TGA and endorsement from the Human Ethics Committee at St Vincent’s.

MGC Pharma is a Stockhead advertiser.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.